Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Estrogen Receptor and/or Progesterone Receptor Positive 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Calcinosis 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Gemcitabine 87Cisplatin 66Cystectomy 38pembrolizumab 34Docetaxel 25Nivolumab 24durvalumab 21Paclitaxel 19Magnetic Resonance Spectroscopy 18Radiotherapy 17Mitomycin 17Carboplatin 16atezolizumab 15Doxorubicin 14Cystoscopy 14BCG Vaccine 13Surveys and Questionnaires 12Standard of Care 12avelumab 11Sunitinib 10tremelimumab 9Transurethral Resection of Bladder 9Ipilimumab 9Filgrastim 9Blood Specimen Collection 9Specimen Handling 8Neoadjuvant Therapy 8Methotrexate 8Methods 8Early Intervention, Educational 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Urinary Bladder Neoplasms × Pharmacogenomic Variants × Clear all
NCT03552796 2023-06-26

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

University of Southern California

Phase 1 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡